NCT05230017 Chinese AntiphosPholipid Syndrome cohorT cOllaborative NEtworks
| NCT ID | NCT05230017 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking Union Medical College Hospital |
| Condition | Anti Phospholipid Syndrome |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2022-10-01 |
| Primary Completion | 2026-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,000 participants in total. It began in 2022-10-01 with a primary completion date of 2026-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by thrombosis and pregnancy morbidity in patients with persistently positive antiphospholipid antibodies (aPLs). However, large-scale research on general population with persistent aPLs has been lacking. This project proposes to establish the first multicenter cohort of patients with persistently positive aPLs in China and conduct a comprehensive clinical phenotyping study. Based on traditional phenotypes of thrombotic and pregnancy events, the focus will be on extra-standard clinical phenotypes and prospective assessment of event risk and prognosis in aPL-positive population. A prospective analysis of extra-standard antibodies will also be conducted to recommend detection criteria for extra-standard antibody application in China and to assess their clinical significance.
Eligibility Criteria
Inclusion Criteria: * The presence of one or more of the antiphospholipid antibodies (aPL) tested according to the 2006 Sapporo APS clasification criteria, on two or more occasions at least 12 weeks apart: Exclusion Criteria: * Patients refuse to participate; * Unable to be followed.
Contact & Investigator
Jiuliang Zhao, M.D.
PRINCIPAL INVESTIGATOR
Peking Union Medical College Hospital
Frequently Asked Questions
Who can join the NCT05230017 clinical trial?
This trial is open to participants of all sexes, studying Anti Phospholipid Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05230017 currently recruiting?
Yes, NCT05230017 is actively recruiting participants. Contact the research team at Jiuliang.zhao@cstar.org.cn for enrollment information.
Where is the NCT05230017 trial being conducted?
This trial is being conducted at Beijing, China, Beijing, China, Fuzhou, China, Guangzhou, China and 11 additional locations.
Who is sponsoring the NCT05230017 clinical trial?
NCT05230017 is sponsored by Peking Union Medical College Hospital. The principal investigator is Jiuliang Zhao, M.D. at Peking Union Medical College Hospital. The trial plans to enroll 2,000 participants.